What is TFA and why does this advice matter?
Trifluoroacetic acid (TFA) is an extremely persistent and highly water-mobile substance formed during the breakdown of numerous other PFAS, including certain fluorinated pesticides, refrigerants and pharmaceuticals. Because TFA barely degrades and spreads easily through groundwater and surface water, it is regarded as one of the hardest PFAS breakdown products to manage. The final scientific opinion of the Risk Assessment Committee (RAC) of the European Chemicals Agency (ECHA) on TFA is now with the European Commission, actuEL-HSE reported on 9 October 2026. ECHA published the final opinion text in early October, formally concluding an assessment that the RAC had already settled in substance back in June of this year.
What exactly does the RAC recommend?
The opinion is the result of a harmonised classification and labelling (CLH) procedure under the European CLP Regulation (EC) No 1272/2008, based on a proposal from Germany. During its 77th plenary meeting, held from 1 to 5 June 2026 in Helsinki (Finland), the RAC adopted by consensus an opinion to classify TFA and its inorganic salts, such as sodium trifluoroacetate, as a reproductive toxicant of category 1B (Repr. 1B, H360Df) due to harm to foetal development. The ‘Df’ suffix denotes category 1B for effects on development of the unborn child and a suspected (category 2) effect on fertility. In addition, for the first time for TFA, the committee recommends classification as a persistent, mobile and toxic substance (PMT, EUH450) and as a very persistent, very mobile substance (vPvM, EUH451), reflecting the risk of long-term, diffuse contamination of groundwater and surface water. For pure TFA, the RAC also recommends a stricter acute toxicity classification by inhalation (from category 4 to 3), a new classification by ingestion (category 4) and the EUH071 statement (corrosive to the respiratory tract). The RAC opinion is scientific in nature and not in itself legally binding; it serves as the basis for a possible amendment to the EU’s harmonised classification list.
What happens next?
Now that the opinion is formally with the European Commission, it is up to the Commission to decide whether TFA’s CLP classification is amended. If the Commission agrees, the new classification becomes binding EU-wide through an amendment to Annex VI of the CLP Regulation, after the usual transition period for manufacturers and importers. Importantly, this CLP classification process is separate from the broader EU discussion on a possible REACH restriction of PFAS as a substance group, although a PMT/vPvM classification could later play a role in restriction proposals. Even so, the impact reaches well beyond the EU: any manufacturer or importer placing TFA, TFA salts or mixtures containing them on the EU market — from chemical companies to producers of refrigerants, pesticides or pharmaceutical intermediates outside Europe — will need to comply with the stricter labelling and documentation requirements once they take effect. For HSE professionals worldwide, this is therefore a process worth following closely, well beyond the EU’s borders: an amended classification feeds through safety data sheets and labels into the entire international supply chain for substances that contain TFA or can break down into it.
Context
Separately from the RAC opinion, an exploratory European biomonitoring study was recently published, commissioned by the Greens/EFA group in the European Parliament and interpreted by researchers at Vrije Universiteit Amsterdam (the Netherlands). TFA was detected in the blood of all 110 participants from nine European countries; no clear difference between men and women was found. That research is not part of the CLH procedure and has not been assessed by the RAC, but it does show how widespread the substance has become, and why TFA is increasingly seen as a distinct regulatory concern.
Source: TFA : l’avis final du RAC transmis à la Commission européenne, 9 October 2026
Additionally researched: ECHA RAC-77 opinion on TFA (plenary meeting 1-5 June 2026, Helsinki), via Food Packaging Forum, ISPRA (Italian national environmental agency) and CIRS; Vrije Universiteit Amsterdam research on TFA in the blood of European volunteers (vu.nl).
